Page 44 - Read Online

Sun et al. J Cancer Metastasis Treat 2019;5:80 I http://dx.doi.org/10.20517/2394-4722.2019.29 Page 7 of 7

33. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8(+) T cells. Nat Rev Immunol 2011;11:645-57.
34. Lorenzo-Herrero S, Lopez-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez AP, Vitale M, et al. NK cell-based immunotherapy in cancer
metastasis. Cancers (Basel) 2018;11.
35. Kriegsman BA, Vangala P, Chen BJ, Meraner P, Brass AL, et al. Frequent loss of IRF2 in cancers leads to immune evasion through
decreased MHC class I antigen presentation and increased PD-L1 expression. J Immunol 2019;203:1999-2010.
36. Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol 2017;31:37-54.
37. Boles KS, Stepp SE, Bennett M, Kumar V, Mathew PA. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin
superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev 2001;181:234-49.
38. Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK
cell function. Mol Immunol 2002;39:1-8.
39. Tai YT, Dillon M, Song W, Leiba M, Li XF, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and
induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112:1329-37.
40. Malaer JD, Mathew PA. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. Am J Cancer Res
2017;7:1637-41.
41. Mathew SO, Chaudhary P, Powers SB, Vishwanatha JK, Mathew PA. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells
inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction. Oncotarget 2016;7:68650-61.
42. Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, et al. Contribution of NK cells to immunotherapy mediated by PD-1/
PD-L1 blockade. J Clin Invest 2018;128:4654-68.
43. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016;17:1025-36.
44. Boles KS, Barten R, Kumaresan PR, Trowsdale J, Mathew PA. Cloning of a new lectin-like receptor expressed on human NK cells.
Immunogenetics 1999;50:1-7.
45. Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, et al. The LLT1 receptor induces IFN-gamma production by human natural
killer cells. Mol Immunol 2004;40:1157-63.
46. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, et al. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory
human NKR-P1A receptor. J Immunol 2005;175:7796-9.
47. Aldemir H, Prod’homme V, Dumaurier MJ, Retiere C, Poupon G, et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161
receptor. J Immunol 2005;175:7791-5.
48. Germain C, Bihl F, Zahn S, Poupon G, Dumaurier MJ, et al. Characterization of alternatively spliced transcript variants of CLEC2D gene. J
Biol Chem 2010;285:36207-15.
49. Rosen DB, Cao W, Avery DT, Tangye SG, Liu YJ, et al. Functional consequences of interactions between human NKR-P1A and its ligand
LLT1 expressed on activated dendritic cells and B cells. J Immunol 2008;180:6508-17.
50. Kita S, Matsubara H, Kasai Y, Tamaoki T, Okabe Y, et al. Crystal structure of extracellular domain of human lectin-like transcript 1 (LLT1),
the ligand for natural killer receptor-P1A. Eur J Immunol 2015;45:1605-13.
51. Skalova T, Blaha J, Harlos K, Duskova J, Koval T, et al. Four crystal structures of human LLT1, a ligand of human NKR-P1, in varied
glycosylation and oligomerization states. Acta Crystallogr D Biol Crystallogr 2015;71:578-91.
52. Tanaka M, Fine JH, Kirkham CL, Aguilar OA, Belcheva A, et al. The inhibitory NKR-P1B:Clr-b recognition axis facilitates detection of
oncogenic transformation and cancer immunosurveillance. Cancer Res 2018;78:3589-603.
53. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM. Genetically linked C-type lectin-related ligands for the NKRP1
family of natural killer cell receptors. Nat Immunol 2003;4:801-7.
54. Carlyle JR, Jamieson AM, Gasser S, Clingan CS, Arase H, et al. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer
cell receptors. Proc Natl Acad Sci U S A 2004;101:3527-32.
55. Germain C, Meier A, Jensen T, Knapnougel P, Poupon G, et al. Induction of lectin-like transcript 1 (LLT1) protein cell surface expression
by pathogens and interferon-gamma contributes to modulate immune responses. J Biol Chem 2011;286:37964-75.
56. Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, et al. Highly effective NK cells are associated with good prognosis in
patients with metastatic prostate cancer. Oncotarget 2015;6:14360-73.
57. Santos-Juanes J, Fernandez-Vega I, Lorenzo-Herrero S, Sordo-Bahamonde C, Martinez-Camblor P, et al. Lectin-like transcript 1 (LLT1)
expression is associated with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma. Arch Dermatol Res
2019;311:369-76.
58. Jindal V. Immunotherapy: a glimmer of hope for metastatic prostate cancer. Chin Clin Oncol 2018;7:61.